Citigroup
IMNM icon

Citigroup’s Immunome IMNM Stock Holding History

Citigroup’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$568K Buy
25,955
+9,499
+58% +$211K ﹤0.01% 3469
2025
Q4 		$353K Buy
16,456
+3,707
+29% +$65.1K ﹤0.01% 3739
2025
Q3 		$149K Sell
12,749
-31,134
-71% -$310K ﹤0.01% 4115
2025
Q2 		$408K Sell
43,883
-101,133
-70% -$829K ﹤0.01% 3745
2025
Q1 		$976K Buy
145,016
+67,780
+88% +$650K ﹤0.01% 3280
2024
Q4 		$820K Buy
77,236
+39,667
+106% +$479K ﹤0.01% 3512
2024
Q3 		$549K Buy
37,569
+15,157
+68% +$215K ﹤0.01% 3675
2024
Q2 		$271K Sell
22,412
-11,009
-33% -$172K ﹤0.01% 3738
2024
Q1 		$825K Sell
33,421
-27,622
-45% -$561K ﹤0.01% 3180
2023
Q4 		$653K Buy
+61,043
New +$508K ﹤0.01% 3200
2021
Q2 		– Sell
-140
Closed -$5K – 6252
2021
Q1 		$5K Sell
140
-95
-40% -$2.36K ﹤0.01% 5892
2020
Q4 		$2K Buy
+235
New +$2.74K ﹤0.01% 7237

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citigroup's IMNM Position: Q1 2026 in Review

Citigroup increased its Immunome (IMNM) stake by 58% in Q1 2026, buying an estimated $211K and bringing the position to 25,955 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

Citigroup first reported a position in IMNM in Q4 2020 and has held it in 12 quarters since. The position peaked at $976K in Q1 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Citigroup held 25,955 shares of Immunome worth $568K as of Q1 2026.
  • Citigroup bought 9,499 Immunome shares in Q1 2026, an estimated $211K.
  • Immunome made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3469 holding.
  • Citigroup first reported a position in Immunome in Q4 2020 and has held it in 12 quarters since.
  • Citigroup's Immunome position peaked at $976K in Q1 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.